MANAGEMENT OF ATYPICAL PARKINSONISM

WNC Teaching session
October 7, 2021

Tanya Simuni, MD
A.C Nielsen Professor of Neurology
Parkinson’s Disease and Movement Disorders Center
Northwestern University, Chicago, USA
Parkinson Foundation Center of Excellence
Disclosures (last 12 months)

- **Dr. Simuni** serves as a consultant for Acadia, Caraway Therapeutics, Critical Path for Parkinson's Consortium (CPP), Denali, General Electric (GE), Neuroderm, Sanofi, Sinopia, Sunovion, Roche, Takeda, MJFF and Voyager.

- **Dr Simuni** is on the Scientific advisory board of Caraway Therapeutics, Neuroderm and Sanofi.

- **Dr. Simuni** has received research funding from Biogen, Roche, Neuroderm, Sanofi, Sun Pharma, Amneal, Prevail, UCB, NINDS, MJFF, Parkinson’s Foundation.
Talk Objectives

• Review symptomatic syndromic management focused on
  • Motor disability
  • Autonomic dysfunction
  • Multidisciplinary care
  • Social support

• Briefly Review Phase 2/3 PD experimental therapeutics for
  • MSA
  • PSP
Key Message

• Unfortunately, there are no disease modifying interventions for any of atypical parkinsonism syndromes.
• Management should be focused on supportive care and quality of life.
• Multidisciplinary care is essential for achieving the goals.
• There is a growing pipeline of experimental therapeutics for MSA and PSP (though all Tau targeted MAB therapeutic studies have been negative so far).
• Burns, McFarland. Current management and emerging therapies in MSA. Neurotherapeutics, 2020
• Palma, Kaufmann. Treatment of autonomic dysfunction in PD and other synucleinopathies. Mov Disorders, 2018
• Progressive supranuclear palsy: advances in diagnosis and management. Parkinsonism and related disorders, 2020
• PSP and CBD: pathophysiology and treatment options. Current TX options neurology 2016